Inter-Individual Variations: A Challenge for the Standardisation of Complement Activation Assays

References

• Sun H, Xia M, Austin CP, Huang R. Paradigm shift in toxicity testing and modeling. AAPS J. 2012;14(3):473–480. doi:10.1208/s12248-012-9358-1
   PubMed Web of Science ®Google Scholar
• Liston A, Humblet-Baron S, Duffy D, Goris A. Human immune diversity: from evolution to modernity. Nat Immunol. 2021;22(12):1479–1489. doi:10.1038/s41590-021-01058-1
   PubMed Web of Science ®Google Scholar
• Revision of EU legislation on hazard classification, labelling and packaging of chemicals. Available from: https://ec.europa.eu/info/law/better-regulation/have-your-say/initiatives/12975-Revision-of-EU-legislation-on-hazard-classification-labelling-and-packaging-of-chemicals_en. Accessed May 20, 2022.
   Google Scholar
• Hempel JC, Poppelaars F, Gaya da Costa M. Distinct in vitro complement activation by various intravenous iron preparations. Am J Nephrol. 2017;45(1):49–59. doi:10.1159/000451060
   PubMed Web of Science ®Google Scholar
• de Jong S, Gagliardi G, Garanto A, et al. Implications of genetic variation in the complement system in age-related macular degeneration. Prog Retin Eye Res. 2021;84:100952. doi:10.1016/j.preteyeres.2021.100952
   PubMed Web of Science ®Google Scholar
• Zhang J, Li S, Hu S, Yu J, Xiang Y. Association between genetic variation of complement C3 and the susceptibility to advanced age-related macular degeneration: a meta-analysis. BMC Ophthalmol. 2018;18(1):274. doi:10.1186/s12886-018-0945-5
   PubMedGoogle Scholar
• Parish ST, Aschner M, Casey W, et al. An evaluation framework for new approach methodologies (NAMs) for human health safety assessment. Regul Toxicol Pharmacol. 2020;112:104592. doi:10.1016/j.yrtph.2020.104592
   PubMed Web of Science ®Google Scholar
• Niethammer M, Burgdorf T, Wistorf E, Schönfelder G, Kleinsorge M. In vitro models of human development and their potential application in developmental toxicity testing. Development. 2022;149(20):dev200933. doi:10.1242/dev.200933
   PubMed Web of Science ®Google Scholar
• Watanabe J, Scornik JC. Measuring human complement activation by HLA antibodies. Arch Pathol Lab Med. 2006;130(3):368–373. doi:10.5858/2006-130-368-MHCABH
   PubMed Web of Science ®Google Scholar
• Mabrouk M, Das DB, Salem ZA, Beherei HH. Nanomaterials for biomedical applications: production, characterisations, recent trends and difficulties. Molecules. 2021;26(4):1077. doi:10.3390/molecules26041077
   PubMed Web of Science ®Google Scholar
• Ramos AP, Cruz MAE, Tovani CB, Ciancaglini P. Biomedical applications of nanotechnology. Biophys Rev. 2017;9(2):79–89. doi:10.1007/s12551-016-0246-2
   PubMedGoogle Scholar
• Khatua A, Priyadarshini E, Rajamani P, et al. Phytosynthesis, characterization and fungicidal potential of emerging gold nanoparticles using pongamia pinnata leave extract: a novel approach in nanoparticle synthesis. J Clust Sci. 2020;31(1):125–131. doi:10.1007/s10876-019-01624-6
   Web of Science ®Google Scholar
• Barabadi H, Tajani B, Moradi M, et al. Penicillium family as emerging nanofactory for biosynthesis of green nanomaterials: a journey into the world of microorganisms. J Clust Sci. 2019;30(4):843–856. doi:10.1007/s10876-019-01554-3
   Web of Science ®Google Scholar
• Aygün A, Gülbağça F, Nas MS, et al. Biological synthesis of silver nanoparticles using Rheum ribes and evaluation of their anticarcinogenic and antimicrobial potential: a novel approach in phytonanotechnology. J Pharm Biomed Anal. 2020;179:113012. doi:10.1016/j.jpba.2019.113012
   PubMed Web of Science ®Google Scholar
• Halamoda‐Kenzaoui B, Holzwarth U, Roebben G, Bogni A, Bremer‐Hoffmann S. Mapping of the available standards against the regulatory needs for nanomedicines. WIREs Nanomed Nanobiotechnol. 2019;11(1). doi:10.1002/wnan.1531
   Google Scholar
• Szebeni J. Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals. Mol Immunol. 2014;61(2):163–173. doi:10.1016/j.molimm.2014.06.038
   PubMed Web of Science ®Google Scholar
• Merkel OM, Urbanics R, Bedőcs P, et al. In vitro and in vivo complement activation and related anaphylactic effects associated with polyethylenimine and polyethylenimine-graft-poly(ethylene glycol) block copolymers. Biomaterials. 2011;32(21):4936–4942. doi:10.1016/j.biomaterials.2011.03.035
   PubMed Web of Science ®Google Scholar
• Jackman JA, Mészáros T, Fülöp T, Urbanics R, Szebeni J, Cho NJ. Comparison of complement activation-related pseudoallergy in miniature and domestic pigs: foundation of a validatable immune toxicity model. Nanomedicine. 2016;12(4):933–943. doi:10.1016/j.nano.2015.12.377
   PubMed Web of Science ®Google Scholar
• Della Camera G, Lipsa D, Mehn D, et al. Approach to improve clinical translation of liposome-based nanomaterials, a focus on innate immune and inflammatory responses. IJMS. 2021;22(2):820. doi:10.3390/ijms22020820
   Google Scholar
• Neun B, Cedrone E, Dobrovolskaia M. NCL Method ITA-5.2. Available from: https://ncihub.org/publications/204/supportingdocs?v=2. Accessed May 20, 2022.
   Google Scholar
• Halamoda-Kenzaoui B, Bremer-Hoffmann S. Main trends of immune effects triggered by nanomedicines in preclinical studies. IJN. 2018;13:5419–5431. doi:10.2147/IJN.S168808
   Google Scholar
• Hartung T, Daston G. Are in vitro tests suitable for regulatory use? Toxicol Sci. 2009;111(2):233–237. doi:10.1093/toxsci/kfp149
   PubMed Web of Science ®Google Scholar
• Wagar LE, DiFazio RM, Davis MM. Advanced model systems and tools for basic and translational human immunology. Genome Med. 2018;10(1):73. doi:10.1186/s13073-018-0584-8
   PubMedGoogle Scholar
• Kim AHJ, Strand V, Sen DP, et al. Association of blood concentrations of complement split product iC 3b and serum C3 with systemic lupus erythematosus disease activity. Arthritis Rheumatol. 2019;71(3):420–430. doi:10.1002/art.40747
   PubMed Web of Science ®Google Scholar
• Capecchi R, Puxeddu I, Pratesi F, Migliorini P. New biomarkers in SLE: from bench to bedside. Rheumatology. 2020;59(Supplement_5):v12–v18. doi:10.1093/rheumatology/keaa484
   PubMedGoogle Scholar
• Schramm EC, Staten NR, Zhang Z, et al. A quantitative lateral flow assay to detect complement activation in blood. Anal Biochem. 2015;477:78–85. doi:10.1016/j.ab.2015.01.024
   PubMed Web of Science ®Google Scholar
• Sandholm K. Development and Evaluation of Immunoassays for Complement Diagnostics [Thesis]. Linnaeus University, Faculty of Health and Life Sciences, Department of Chemistry and Biomedical Sciences; 2019. Available from: http://urn.kb.se/resolve?urn=urnnbn:se:lnu:diva-90125:. Accessed May 20, 2022.
   Google Scholar
• Peerschke EI, Valentino A, So RJ, Shulman S. Thromboinflammation supports complement activation in cancer patients with COVID-19. Front Immunol. 2021;12:716361. doi:10.3389/fimmu.2021.716361
   PubMed Web of Science ®Google Scholar
• Sharif SN, Goldberg B. Investigation of complement activation in patients with chronic idiopathic urticaria. J Allergy and Clin Immunol. 2007;119(1):S200. doi:10.1016/j.jaci.2006.12.151
   Web of Science ®Google Scholar
• Java A, Baciu P, Widjajahakim R, et al. Functional analysis of rare genetic variants in complement factor I (CFI) using a serum-based assay in advanced age-related macular degeneration. Trans Vis Sci Tech. 2020;9(9):37. doi:10.1167/tvst.9.9.37
   PubMed Web of Science ®Google Scholar
• Skattum L. Clinical complement analysis—an overview. Transfus Med Rev. 2019;33(4):207–216. doi:10.1016/j.tmrv.2019.09.001
   PubMed Web of Science ®Google Scholar
• Caputo F, Clogston J, Calzolai L, Rösslein M, Prina-Mello A. Measuring particle size distribution of nanoparticle enabled medicinal products, the joint view of EUNCL and NCI-NCL. A step by step approach combining orthogonal measurements with increasing complexity. J Control Release. 2019;299:31–43. doi:10.1016/j.jconrel.2019.02.030
   PubMed Web of Science ®Google Scholar
• Liptrott N. Analysis of complement activation by EIA. Available from: https://www.euncl.org/about-us/assay-cascade/PDFs/Haematology/EUNCL-ITA-005_2.pdf?m=1526624464&. Accessed May 20, 2022.
   Google Scholar
• Neun B, Ilinskaya A, Dobrovolskaia M. NCL Method ITA-5.1. Available from: https://ncihub.org/publications/133/supportingdocs?v=3. Accessed May 20, 2022.
   Google Scholar
• Bergseth G, Ludviksen JK, Kirschfink M, Giclas PC, Nilsson B, Mollnes TE. An international serum standard for application in assays to detect human complement activation products. Mol Immunol. 2013;56(3):232–239. doi:10.1016/j.molimm.2013.05.221
   PubMed Web of Science ®Google Scholar
• Benasutti H, Wang G, Vu VP, et al. Variability of complement response toward preclinical and clinical nanocarriers in the general population. Bioconjugate Chem. 2017;28(11):2747–2755. doi:10.1021/acs.bioconjchem.7b00496
   PubMed Web of Science ®Google Scholar
• Brodin P, Davis MM. Human immune system variation. Nat Rev Immunol. 2017;17(1):21–29. doi:10.1038/nri.2016.125
   PubMed Web of Science ®Google Scholar
• Lakshmikanth T, Muhammad SA, Olin A, et al. Human immune system variation during 1 year. Cell Rep. 2020;32(3):107923. doi:10.1016/j.celrep.2020.107923
   PubMed Web of Science ®Google Scholar